India's Most Valuable Companies 2025 edition · Source: Hurun India
- Valuation
- ₹42,700 Cr
- 1-year change
- +185%
2024 #369 2023 #340 2022 #318
Anthem Biosciences Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Active Listed - NSE: ANTHEM · BSE: 544449 Public Limited Company pharma India's Most Valuable Nifty 500
Market Cap
₹45,788 Cr
ANTHEM · NSE
Share Price
₹813.95
+0.14% today
Revenue
₹2,124 Cr
FY 2025-26 · +15.2% YoY
EBITDA
₹810 Cr
Margin 38.1%
Net Profit
₹607 Cr
FY 2025-26 · +34.5% YoY
P/E (TTM)
76.5x
P/B 14.9x
ROE
21.7%
ROCE 29.3%
Debt / Equity
0.03
Interest cover 1.1x
About Anthem Biosciences Limited
Data last updated:
Anthem Biosciences Limited is a public limited company based in Bangalore, Karnataka, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 13 June 2006 and has been in existence for over 20 years.
Anthem Biosciences is part of the Nifty 500 index. Its director Ajay Bhardwaj is #113 among India's richest people (2026). Its director K Ravindra Chandrappa is #571 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L24233KA2006PLC039703. Its GSTIN is 29AAFCA7588P1ZN (Karnataka). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 544449 and NSE: ANTHEM.
The company has an authorised share capital of ₹125 Cr and a paid-up capital of ₹112.68 Cr. It is led by directors including Ajay Bhardwaj (Managing Director) and Ganesh Sambasivam (Whole-Time Director).
Its last annual general meeting (AGM) was held on 10 June 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Bangalore, Karnataka.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,124.33 Cr, a growth of 15.2% compared to the previous year. For the same year it recorded a net profit of ₹607.38 Cr (net margin 28.6%) and EBITDA of ₹809.58 Cr (EBITDA margin 38.1%). The net worth stands at ₹3,042.51 Cr (up 26.3% YoY). Total assets are valued at ₹3,128.88 Cr (up 23% YoY).
The company has about 1,876 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Anthem Biosciences. As per MCA filings, the company has open charges of ₹311.21 Cr and satisfied charges of ₹484.38 Cr on record. Court records list 11 cases involving the company, including 5 filed by the company and 6 filed against it; 4 cases are pending. The company has 16 deals on record (7 secondary share transfers, 5 funding rounds, 3 market trades), with disclosed funding of ₹644.84 Cr; the latest was in June 2026. Its 4 peer companies in the Pharma industry (Biosciences, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Laurus Labs Limited with revenue of ₹5,613.89 Cr. The company has 13 MSME Form 1 returns on record between 2017 and 2024, listing 244 overdue payments to 114 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anthembio.com.
Company details
CIN L24233KA2006PLC039703
Registration Number 039703
Incorporation Date 13 June 2006
ROC Bangalore
Listing Status Listed - Listed on NSE (ANTHEM); Listed on BSE (544449)
Company Status Active
Date of Last AGM 10 June 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Anthem Biosciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24233KA2006PLC039703, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233KA2006PLC039703 | Current |
| U24233KA2006PTC039703 | Previous |
| U24233KA2006PLC039703 | Previous |
Key People
Ajay Bhardwaj Managing Director Ganesh Sambasivam Whole-Time Director K Ravindra Chandrappa Whole-Time Director Recognitions & Rankings of Anthem Biosciences
India's Richest People 2026 edition · 3 directors · Source: Hurun India
- #113 Ajay Bhardwaj ₹28,800 Cr
- #571 K Ravindra Chandrappa ₹5,900 Cr
- #571 Ganesh Sambasivam ₹5,900 Cr
Stock market indices
Nifty 500
Contact details
Anthem Biosciences Limited's registered office is in Bangalore, Karnataka. Its website is anthembio.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressNo. 49 F1 & F2 Canara Bank Road Bommasandra Industrial Area Phase I Bo, Mmasandra, Bangalore, Karnataka, India – 560099
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Anthem Biosciences Limited, buy the company report.
Comprehensive company report
Anthem Biosciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Anthem Biosciences operates one associated brand: Anthem Biosciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Developer of integrated contract research development and manufacturing services | anthembio.com |
Business activity
The main business activities of Anthem Biosciences are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and scientific research and development. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Anthem Biosciences Limited, buy the company report.
Financials of Anthem Biosciences Limited
FY 2025-26 filings availableAnthem Biosciences Limited reported revenue of ₹2,124.33 Cr (up 15.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹2,124 Cr
+15.2% YoY
EBITDA
₹810 Cr
+20.6% YoY
Profit After Tax
₹607 Cr
+34.5% YoY
Net Worth
₹3,043 Cr
+26.3% YoY
Total Assets
₹3,129 Cr
+23.0% YoY
Total Debt
₹53.93 Cr
-52.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,124 | 1,845 | 1,419 | 1,057 | 1,231 | 1,103 | 633 |
| Revenue growth | +15.2% | +30.0% | +34.3% | -14.2% | +11.6% | +74.4% | - |
| EBITDA | 810 | 671 | 505 | 431 | 565 | 408 | 182 |
| EBITDA margin | +38.1% | +36.4% | +35.6% | +40.8% | +45.9% | +37.0% | +28.8% |
| Profit before tax | 824 | 657 | 477 | 497 | 546 | 366 | 121 |
| Net profit | 607 | 452 | 368 | 344 | 406 | 271 | 92.64 |
| Net profit margin | +28.6% | +24.5% | +25.9% | +32.6% | +33.0% | +24.6% | +14.6% |
| EPS (₹) | 10.54 | 8.07 | 6.57 | 6.75 | 462.08 | 319.75 | 110.63 |
| Balance sheet | |||||||
| Total assets | 3,129 | 2,545 | 2,182 | 1,880 | 1,425 | 829 | 604 |
| Net worth | 3,043 | 2,410 | 1,925 | 1,741 | 1,355 | 701 | 422 |
| Total debt | 53.93 | 113 | 239 | 126 | 35.49 | 100 | 159 |
| Cash & bank | 275 | 172 | 184 | 343 | 349 | 40.77 | 22.43 |
| Net working capital | 837 | 913 | 806 | 696 | 631 | 202 | 121 |
| Cash flow | |||||||
| Cash from operations | 844 | 271 | 140 | 306 | 333 | 278 | 166 |
| Cash from investing | (702) | (147) | (221) | (376) | (205) | (196) | (109) |
| Cash from financing | (40.00) | (136) | (77.18) | 63.97 | 181 | (63.27) | (47.63) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 418 | 611 | 423 | 550 | 540 | 483 | 498 | 525 |
| Revenue growth (YoY) | -22.6% | +26.4% | -15.0% | +4.8% | +59.6% | - | - | - |
| Other income | 24.89 | 52.19 | 33.53 | 48.23 | 22.81 | 14.06 | 24.37 | 27.85 |
| EBITDA | 151 | 267 | 132 | 218 | 191 | 195 | 160 | 195 |
| EBITDA margin | +36.0% | +43.7% | +31.2% | +39.6% | +35.4% | +40.4% | +32.0% | +37.2% |
| Depreciation | 29.99 | 39.59 | 34.53 | 33.50 | 26.45 | 30.42 | 20.28 | 19.99 |
| Interest | 0.89 | 1.90 | 0.35 | 3.03 | 1.61 | 0.52 | 2.55 | 3.55 |
| Profit before tax | 145 | 278 | 130 | 230 | 186 | 178 | 161 | 200 |
| Tax | 24.64 | 88.16 | 37.66 | 56.17 | 50.46 | 95.69 | 36.71 | 37.60 |
| Net profit | 120 | 190 | 92.82 | 173 | 136 | 82.63 | 124 | 162 |
| EPS (₹) | 2.11 | 3.34 | 1.64 | 3.09 | 2.42 | 1.47 | 0.00 | 2.84 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,089 | 1,841 | 1,418 | 1,057 | 1,231 | 1,103 | 633 |
| Revenue growth | +13.5% | +29.9% | +34.1% | -14.2% | +11.6% | +74.4% | - |
| EBITDA | 827 | 689 | 505 | 431 | 565 | 408 | 182 |
| EBITDA margin | +39.6% | +37.4% | +35.6% | +40.8% | +45.9% | +37.0% | +28.8% |
| Profit before tax | 903 | 711 | 485 | 498 | 547 | 366 | 121 |
| Net profit | 686 | 506 | 375 | 345 | 406 | 271 | 92.64 |
| Net profit margin | +32.9% | +27.5% | +26.5% | +32.6% | +33.0% | +24.6% | +14.6% |
| EPS (₹) | 11.94 | 9.05 | 6.70 | 6.76 | 462.60 | 319.76 | 110.63 |
| Balance sheet | |||||||
| Total assets | 3,266 | 2,608 | 2,125 | 1,870 | 1,426 | 829 | 604 |
| Net worth | 3,185 | 2,473 | 1,933 | 1,742 | 1,355 | 701 | 422 |
| Total debt | 50.03 | 113 | 173 | 115 | 35.49 | 100 | 159 |
| Cash & bank | 270 | 166 | 184 | 343 | 349 | 40.62 | 22.43 |
| Net working capital | 761 | 875 | 787 | 703 | 631 | 202 | 121 |
| Cash flow | |||||||
| Cash from operations | 889 | 300 | 164 | 319 | 333 | 278 | 166 |
| Cash from investing | (742) | (250) | (192) | (378) | (206) | (196) | (109) |
| Cash from financing | (43.55) | (68.47) | (132) | 52.85 | 181 | (63.27) | (47.63) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 384 | 582 | 417 | 552 | 538 | 479 | 498 | 525 |
| Revenue growth (YoY) | -28.7% | +21.6% | -16.4% | +5.2% | +58.9% | - | - | - |
| Other income | 28.60 | 61.60 | 39.92 | 53.80 | 27.73 | 37.82 | 24.34 | 27.83 |
| Total expenses | 253 | 316 | 279 | 327 | 343 | 281 | 331 | 324 |
| EBITDA | 131 | 267 | 138 | 226 | 195 | 198 | 167 | 201 |
| EBITDA margin | +34.1% | +45.8% | +33.1% | +40.9% | +36.3% | +41.4% | +33.5% | +38.3% |
| Depreciation | 22.31 | 26.28 | 26.75 | 23.92 | 22.61 | 20.99 | 19.50 | 19.11 |
| Interest | 0.76 | 1.58 | 1.13 | 2.23 | 1.61 | 2.10 | 1.79 | 2.56 |
| Profit before tax | 136 | 301 | 150 | 253 | 199 | 213 | 170 | 207 |
| Tax | 34.36 | 89.06 | 37.99 | 54.87 | 50.60 | 90.27 | 41.91 | 36.67 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 418 | 611 | 423 | 550 | 540 | 483 | 498 | 525 |
| Revenue growth (YoY) | -22.6% | +26.4% | -15.0% | +4.8% | +59.6% | - | - | - |
| Other income | 24.89 | 52.19 | 33.53 | 48.23 | 22.81 | 14.06 | 24.37 | 27.85 |
| EBITDA | 151 | 267 | 132 | 218 | 191 | 195 | 160 | 195 |
| EBITDA margin | +36.0% | +43.7% | +31.2% | +39.6% | +35.4% | +40.4% | +32.0% | +37.2% |
| Depreciation | 29.99 | 39.59 | 34.53 | 33.50 | 26.45 | 30.42 | 20.28 | 19.99 |
| Interest | 0.89 | 1.90 | 0.35 | 3.03 | 1.61 | 0.52 | 2.55 | 3.55 |
| Profit before tax | 145 | 278 | 130 | 230 | 186 | 178 | 161 | 200 |
| Tax | 24.64 | 88.16 | 37.66 | 56.17 | 50.46 | 95.69 | 36.71 | 37.60 |
| Net profit | 120 | 190 | 92.82 | 173 | 136 | 82.63 | 124 | 162 |
| EPS (₹) | 2.11 | 3.34 | 1.64 | 3.09 | 2.42 | 1.47 | 0.00 | 2.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,124 | 1,845 | 1,419 | 1,057 | 1,231 | 1,103 | 633 |
| Revenue growth | +15.2% | +30.0% | +34.3% | -14.2% | +11.6% | +74.4% | - |
| Other income | 156 | 85.73 | 63.70 | 139 | 48.98 | 37.21 | 20.76 |
| Total expenses | 1,315 | 1,174 | 914 | 626 | 666 | 696 | 451 |
| Employee cost | 281 | 260 | 183 | 153 | 138 | 142 | 120 |
| EBITDA | 810 | 671 | 505 | 431 | 565 | 408 | 182 |
| EBITDA margin | +38.1% | +36.4% | +35.6% | +40.8% | +45.9% | +37.0% | +28.8% |
| Depreciation | 134 | 89.37 | 81.82 | 63.70 | 57.76 | 62.40 | 61.58 |
| Interest | 7.06 | 10.53 | 9.66 | 8.72 | 10.09 | 16.97 | 20.43 |
| Profit before tax | 824 | 657 | 477 | 497 | 546 | 366 | 121 |
| Tax | 232 | 206 | 110 | 112 | 141 | 94.27 | 27.96 |
| Net profit | 607 | 452 | 368 | 344 | 406 | 271 | 92.64 |
| Net profit margin | +28.6% | +24.5% | +25.9% | +32.6% | +33.0% | +24.6% | +14.6% |
| EPS (₹) | 10.54 | 8.07 | 6.57 | 6.75 | 462.08 | 319.75 | 110.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 112 | 112 | 112 | 114 | 8.78 | 8.48 | 8.38 |
| Reserves & surplus | 2,930 | 2,298 | 1,813 | 1,627 | 1,346 | 693 | 413 |
| Shareholders' funds (net worth) | 3,043 | 2,410 | 1,925 | 1,741 | 1,355 | 701 | 422 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 51.07 | 109 | 151 | 116 | 35.49 | 100 | 101 |
| Unsecured loans | 2.86 | 4.36 | 87.79 | 9.83 | 0.00 | 0.00 | 57.52 |
| Total debt | 53.93 | 113 | 239 | 126 | 35.49 | 100 | 159 |
| Total liabilities | 3,129 | 2,545 | 2,182 | 1,880 | 1,425 | 829 | 604 |
| Assets | |||||||
| Gross block | 1,507 | 1,301 | 996 | 884 | 707 | 682 | 567 |
| Net block | 783 | 705 | 483 | 449 | 329 | 361 | 306 |
| Capital work in progress | 264 | 297 | 345 | 164 | 154 | 18.68 | 49.81 |
| Investments | 1,007 | 433 | 472 | 499 | 273 | 209 | 98.66 |
| Inventories | 125 | 340 | 211 | 129 | 58.23 | 35.06 | 125 |
| Sundry debtors | 591 | 450 | 490 | 274 | 326 | 255 | 105 |
| Cash & bank balances | 275 | 172 | 184 | 343 | 349 | 40.77 | 22.43 |
| Loans & advances | 148 | 213 | 136 | 83.96 | 91.55 | 76.20 | 51.39 |
| Total current assets | 1,138 | 1,176 | 1,022 | 830 | 825 | 407 | 304 |
| Total current liabilities | 300 | 263 | 216 | 135 | 194 | 205 | 184 |
| Net working capital | 837 | 913 | 806 | 696 | 631 | 202 | 121 |
| Total assets | 3,129 | 2,545 | 2,182 | 1,880 | 1,425 | 829 | 604 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 172 | 184 | 343 | 349 | 40.77 | 22.43 | 13.90 |
| Net cash from operating activities | 844 | 271 | 140 | 306 | 333 | 278 | 166 |
| Net cash from investing activities | (702) | (147) | (221) | (376) | (205) | (196) | (109) |
| Net cash from financing activities | (40.00) | (136) | (77.18) | 63.97 | 181 | (63.27) | (47.63) |
| Net change in cash | 103 | (12.08) | (158) | (6.06) | 308 | 18.34 | 8.53 |
| Closing cash | 275 | 172 | 184 | 343 | 349 | 40.77 | 22.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +15.2% | +30.0% | +34.3% | -14.2% | +11.6% | +74.4% | - |
| EBITDA growth | +20.7% | +32.9% | +17.2% | -23.8% | +38.6% | +124.1% | - |
| PBT growth | +25.5% | +37.6% | -4.0% | -8.9% | +49.4% | +203.0% | +9997.0% |
| Net income growth | +34.5% | +22.9% | +6.7% | -15.1% | +49.5% | +193.0% | - |
| Revenue CAGR (3Y) | +26.2% | +14.4% | +8.8% | +18.7% | - | - | - |
| EBITDA CAGR (3Y) | +23.4% | +5.9% | +7.4% | +33.3% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.9% | +24.5% | +25.9% | +36.4% | +32.9% | +24.6% | +14.7% |
| Return on capital employed | +29.3% | +28.2% | +24.0% | +27.4% | +49.4% | +53.4% | +23.4% |
| Return on net worth | +21.7% | +20.8% | +20.0% | +22.3% | +39.4% | +48.3% | +22.0% |
| Debt / equity | 0.03 | 0.08 | 0.10 | 0.05 | 0.07 | 0.23 | 0.38 |
| Long-term debt / equity | 0.01 | 0.04 | 0.06 | 0.03 | 0.01 | 0.10 | 0.23 |
| Interest cover | 1.05 | 1.81 | 2.28 | 2.38 | 1.99 | 4.91 | 16.98 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.51 | 1.61 | 1.51 | 1.33 | 1.77 | 1.77 | 1.12 |
| Inventory turnover | 9.14 | 6.69 | 8.33 | 11.26 | 26.40 | 13.75 | 5.05 |
| Debtors turnover | 4.08 | 3.92 | 3.71 | 3.52 | 4.24 | 6.13 | 6.02 |
| EPS (₹) | 10.54 | 8.07 | 6.57 | 6.75 | 462.08 | 319.75 | 110.63 |
| Dividend per share (₹) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 54.16 | 43.10 | 34.43 | 30.51 | 1,543.93 | 826.75 | 503.43 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 384 | 582 | 417 | 552 | 538 | 479 | 498 | 525 |
| Revenue growth (YoY) | -28.7% | +21.6% | -16.4% | +5.2% | +58.9% | - | - | - |
| Other income | 28.60 | 61.60 | 39.92 | 53.80 | 27.73 | 37.82 | 24.34 | 27.83 |
| Total expenses | 253 | 316 | 279 | 327 | 343 | 281 | 331 | 324 |
| EBITDA | 131 | 267 | 138 | 226 | 195 | 198 | 167 | 201 |
| EBITDA margin | +34.1% | +45.8% | +33.1% | +40.9% | +36.3% | +41.4% | +33.5% | +38.3% |
| Depreciation | 22.31 | 26.28 | 26.75 | 23.92 | 22.61 | 20.99 | 19.50 | 19.11 |
| Interest | 0.76 | 1.58 | 1.13 | 2.23 | 1.61 | 2.10 | 1.79 | 2.56 |
| Profit before tax | 136 | 301 | 150 | 253 | 199 | 213 | 170 | 207 |
| Tax | 34.36 | 89.06 | 37.99 | 54.87 | 50.60 | 90.27 | 41.91 | 36.67 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,089 | 1,841 | 1,418 | 1,057 | 1,231 | 1,103 | 633 |
| Revenue growth | +13.5% | +29.9% | +34.1% | -14.2% | +11.6% | +74.4% | - |
| Other income | 182 | 109 | 70.52 | 139 | 48.98 | 37.21 | 20.76 |
| Total expenses | 1,262 | 1,151 | 913 | 626 | 666 | 696 | 451 |
| Employee cost | 262 | 252 | 183 | 153 | 138 | 142 | 120 |
| EBITDA | 827 | 689 | 505 | 431 | 565 | 408 | 182 |
| EBITDA margin | +39.6% | +37.4% | +35.6% | +40.8% | +45.9% | +37.0% | +28.8% |
| Depreciation | 99.57 | 77.94 | 81.49 | 63.70 | 57.76 | 62.40 | 61.58 |
| Interest | 6.71 | 9.29 | 9.26 | 8.71 | 10.09 | 16.97 | 20.43 |
| Profit before tax | 903 | 711 | 485 | 498 | 547 | 366 | 121 |
| Tax | 233 | 205 | 110 | 112 | 141 | 94.27 | 27.96 |
| Net profit | 686 | 506 | 375 | 345 | 406 | 271 | 92.64 |
| Net profit margin | +32.9% | +27.5% | +26.5% | +32.6% | +33.0% | +24.6% | +14.6% |
| EPS (₹) | 11.94 | 9.05 | 6.70 | 6.76 | 462.60 | 319.76 | 110.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 112 | 112 | 112 | 114 | 8.78 | 8.48 | 8.38 |
| Reserves & surplus | 3,072 | 2,361 | 1,821 | 1,628 | 1,347 | 693 | 413 |
| Shareholders' funds (net worth) | 3,185 | 2,473 | 1,933 | 1,742 | 1,355 | 701 | 422 |
| Secured loans | 47.17 | 109 | 167 | 105 | 35.49 | 100 | 101 |
| Unsecured loans | 2.86 | 4.36 | 5.99 | 9.83 | 0.00 | 0.00 | 57.52 |
| Total debt | 50.03 | 113 | 173 | 115 | 35.49 | 100 | 159 |
| Total liabilities | 3,266 | 2,608 | 2,125 | 1,870 | 1,426 | 829 | 604 |
| Assets | |||||||
| Gross block | 1,290 | 1,208 | 991 | 884 | 707 | 682 | 567 |
| Net block | 613 | 624 | 478 | 449 | 329 | 361 | 306 |
| Capital work in progress | 83.52 | 57.94 | 156 | 143 | 153 | 18.59 | 49.81 |
| Investments | 1,380 | 533 | 472 | 499 | 273 | 209 | 98.66 |
| Inventories | 119 | 339 | 211 | 129 | 58.23 | 35.06 | 125 |
| Sundry debtors | 573 | 448 | 490 | 274 | 326 | 255 | 105 |
| Cash & bank balances | 270 | 166 | 184 | 343 | 349 | 40.62 | 22.43 |
| Loans & advances | 63.91 | 150 | 101 | 80.47 | 90.81 | 76.20 | 51.39 |
| Total current assets | 1,026 | 1,103 | 986 | 827 | 824 | 407 | 304 |
| Total current liabilities | 265 | 228 | 200 | 123 | 193 | 205 | 184 |
| Net working capital | 761 | 875 | 787 | 703 | 631 | 202 | 121 |
| Total assets | 3,266 | 2,608 | 2,125 | 1,870 | 1,426 | 829 | 604 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 166 | 184 | 343 | 349 | 40.62 | 22.43 | 13.90 |
| Net cash from operating activities | 889 | 300 | 164 | 319 | 333 | 278 | 166 |
| Net cash from investing activities | (742) | (250) | (192) | (378) | (206) | (196) | (109) |
| Net cash from financing activities | (43.55) | (68.47) | (132) | 52.85 | 181 | (63.27) | (47.63) |
| Net change in cash | 104 | (17.60) | (159) | (6.07) | 308 | 18.19 | 8.53 |
| Closing cash | 270 | 166 | 184 | 343 | 349 | 40.62 | 22.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.5% | +29.9% | +34.1% | -14.2% | +11.6% | +74.4% | - |
| EBITDA growth | +20.0% | +36.5% | +17.2% | -23.8% | +38.7% | +124.1% | - |
| PBT growth | +26.9% | +46.8% | -2.6% | -8.9% | +49.5% | +203.0% | +6.1% |
| Net income growth | +35.6% | +35.1% | +8.8% | -15.1% | +49.6% | +193.0% | - |
| Revenue CAGR (3Y) | +25.5% | +14.3% | +8.7% | +18.7% | +25.3% | - | - |
| EBITDA CAGR (3Y) | +24.3% | +6.8% | +7.4% | +33.3% | +48.8% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +32.1% | +27.5% | +26.4% | +36.5% | +33.0% | +24.6% | +14.7% |
| Return on capital employed | +31.0% | +30.5% | +24.7% | +27.5% | +49.4% | +53.4% | +24.9% |
| Return on net worth | +23.7% | +23.0% | +20.4% | +22.3% | +39.5% | +48.3% | +24.6% |
| Debt / equity | 0.03 | 0.06 | 0.08 | 0.05 | 0.07 | 0.23 | 0.47 |
| Long-term debt / equity | 0.01 | 0.03 | 0.04 | 0.03 | 0.01 | 0.10 | 0.31 |
| Interest cover | 0.92 | 1.52 | 2.19 | 2.37 | 1.99 | 4.91 | 16.98 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.67 | 1.67 | 1.51 | 1.33 | 1.77 | 1.77 | 1.17 |
| Inventory turnover | 9.13 | 6.69 | 8.32 | 11.26 | 26.40 | 13.75 | 5.83 |
| Debtors turnover | 4.09 | 3.93 | 3.71 | 3.52 | 4.24 | 6.13 | 5.69 |
| EPS (₹) | 11.94 | 9.05 | 6.70 | 6.76 | 462.60 | 319.76 | 110.63 |
| Dividend per share (₹) | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 56.70 | 44.24 | 34.58 | 30.53 | 1,544.46 | 826.76 | 503.43 |
To see the full year-wise statements and ratios of Anthem Biosciences Limited, buy the company report.
Board of directors of Anthem Biosciences Limited
Anthem Biosciences has 8 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ganesh Sambasivam | Whole-Time Director | 04 Aug 2006 | 20 Years 2 Months | Current |
| Ajay Bhardwaj | Managing Director | 13 Jun 2006 | 20 Years 4 Months | Current |
| Shubha Kulkarni Also directs: Arvo Technologies LLP, Jobsforher Restart Portal Private Limited, Altissimo Consulting and Services Private Limited and 1 more | Director | 27 Sep 2024 | 2 Years 0 Months | Current |
| K Ravindra Chandrappa Also directs: Neoanthem Lifesciences Private Limited, KCR Ventures LLP, Ravisika Hospitality LLP and 1 more | Whole-Time Director | 27 Sep 2006 | 20 Years 0 Months | Current |
| Ramadurai Ramesh Also directs: Bosch Limited, Centum Electronics Limited | Director | 27 Sep 2024 | 2 Years 0 Months | Current |
| Satish Chander Subbanna | Nominee Director | 09 Apr 2021 | 5 Years 6 Months | Current |
Showing 6 of 8 current directors. View all directors
Peer comparison
Anthem Biosciences Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Biosciences, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Laurus Labs Limited | ₹5,613.89 Cr (FY 2025) | 11.0% | Anakapalle, Andhra Pradesh, India | |||
| Amneal Pharmaceuticals Private Limited | ₹2,944.87 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Anthem Biosciences Limitedthis company | ₹2,124.33 Cr (FY 2026) | ₹607.38 Cr | 28.6% | 15.2% | 1,876 | Bangalore, Karnataka, India |
| Indoco Remedies Limited | ₹1,670.37 Cr (FY 2025) | -9.0% | Mumbai, Maharashtra, India | |||
| Onesource Specialty Pharma Limited | ₹1,462.33 Cr (FY 2025) | 730.0% | Thane, Maharashtra, India |
To see the full peer comparison of Anthem Biosciences Limited, buy the company report.
Auditor
Anthem Biosciences Limited is audited by K.P. Rao & Co. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K.P. Rao & Co. | FY 2024 | 003135 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 71.40%, foreign institutional investors hold 2.60%, domestic institutional investors hold 13.40% and retail and other public shareholders hold 12.60%.
Sep 2026
QUARTER
71.40% Promoters
13.40% DII (Domestic Institutional)
2.60% FII (Foreign Institutional)
12.60% Retail & Others
Promoter holding - history
Now 71.40% · Sep 2026High 74.70% · Dec 2025Low 71.40% · Sep 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 71.40% | 74.70% | 74.70% | 74.70% |
| Public | 28.60% | 25.30% | 25.30% | 25.30% |
Charges & borrowings
Open charges
₹311.21 Cr
Satisfied charges
₹484.38 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Sep 2022 | 100608841 | Citi Bank N.A. | ₹125 Cr | Open | |
| 16 May 2017 | 100114200 | Hdfc Bank Limited | ₹25 Cr | Open | |
| 14 Feb 2017 | 100080421 | Others | ₹11.21 Cr | Open | |
| 26 May 2014 | 10508137 | Citi Bank N.A. | ₹150 Cr | Open | |
| 16 Feb 2023 | 100684784 | Others | ₹204 Cr | Satisfied |
To see the full charge records of Anthem Biosciences Limited, buy the company report.
Total charge records: 14 View all charges
Deals & funding
Anthem Biosciences Limited has 16 deals on record (7 secondary share transfers, 5 funding rounds, 3 market trades), with disclosed funding of ₹644.84 Cr; the latest was in June 2026.
Total deals
16
Secondary share transfers
7
Funding rounds
5
Market trades
3
IPO
1
Disclosed funding
₹644.84 Cr
Deals on record (5 of 16)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2026 | Market trade | ₹1,274.7 Cr | Seller: an individual |
| Mar 2026 | Market trade | ₹1,261.71 Cr | Buyer: Hdfc Mutual Fund, Sbi Mutual Fund Seller: Viridity Tone LLP |
| Jul 2025 | IPO | ₹3,395 Cr | Investors: Abu Dhabi Investment Authority, Government Pension Fund Global, Jupiter India Fund Seller: Viridity Tone LLP , Portsmouth Technologies LLC, 2 individuals |
| Dec 2024 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: True North |
| Sep 2024 | Secondary share transfer | Undisclosed | Buyer: Swara Trust, 3 individuals Seller: 2 individuals |
To see the full deal history of Anthem Biosciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Anthem Biosciences Limited has 11 court cases on record: 5 filed by Anthem Biosciences, 6 filed against it. 4 cases are pending and 7 are disposed.
Total cases
11
Filed by the company
5
Filed against the company
6
Pending
4
Disposed
7
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 9 | 5 | 3 |
| High courts | 2 | 1 | 1 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Court case (Com.O.S.) | Filed by the company against Kavi Protein and Feed Private Limited | Pending |
| District court, BENGALURU, Karnataka | Civil suit | Filed by the company against Makin Laboratories Pvt Ltd | Disposed |
| District court, BENGALURU RURAL, Karnataka | Court case (Com.O.S.) | Filed by the company against Vivimed Labs Ltd | Disposed |
| District court, RAMANAGARA, Karnataka | Interim or miscellaneous application | Filed against the company by an individual | Pending |
| High Court | Court case (CRL.P) | Filed by the company against State of Karnataka and 1 other | Pending |
To see the full case history of Anthem Biosciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Anthem Biosciences Limited was last rated by Icra on 18 May 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 18 May 2022 |
To see the full credit ratings and regulatory alerts of Anthem Biosciences Limited, buy the company report.
MSME payment delays
Anthem Biosciences Limited has 13 MSME Form 1 returns on record between 2017 and 2024, listing 244 overdue payments to 114 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 114)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Ultra International | |||
| Space Geo Tech | |||
| S.V.Scientific Private Limited | |||
| Pharmalab India Private Limited. |
To see the full MSME payment records of Anthem Biosciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Anthem Biosciences has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Neoanthem Lifesciences Private Limited | U24239KA2020PTC136337 |
To see the full group structure of Anthem Biosciences Limited, buy the company report.
Employees & EPFO
Anthem Biosciences Limited has a workforce of 1,876 employees on its EPFO records as of Sep 17, 2025, across 1 active EPFO establishment.
Employee count
1,876
Active EPFO establishments
1
Employee growth
5.57%
GST
Anthem Biosciences has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAFCA7588P1ZN | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Anthem Biosciences Limited, buy the company report.
Recent activity
Anthem Biosciences Limited has 11 board changes on record since 2006: 9 appointments and 2 cessations. The latest: Ganesh Sambasivam ceased to be Director on 09 Jun 2025.
Filing
Anthem Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Bangalore.
AGM
Anthem Biosciences Limited last Annual general meeting of members was held on 10 Jun 2025 as per latest MCA records.
Ceased
Ganesh Sambasivam ceased to be Director.
Ceased
K Ravindra Chandrappa ceased to be Director.
Charges
A charge registered on 16 Feb 2023 via Charge ID 100684784 with Others was fully satisfied on 23 Apr 2025.
Charges
A charge with Citi Bank N.A. of Rs. 150.00 Cr registered on 26 May 2014 with Charge ID 10508137 was modified on 05 Mar 2025.
Appointed
Ramadurai Ramesh was appointed as Director.
Appointed
Ravikant Uppal was appointed as Director.
Appointed
Shubha Kulkarni was appointed as Director.
Appointed
Subramanian Madhavan was appointed as Director.
Charges
A charge with Citi Bank N.A. of Rs. 125.00 Cr registered on 15 Sep 2022 with Charge ID 100608841 was modified on 06 Sep 2024.
Appointed
Mohammed Gawir Baig was appointed as CFO.
34 earlier events are in the company report.
News
ANTHEM: RS. 249.90 CRORES BSE BLOCK TRADE; FOR ~ 3,000,000 SHARES, AT RS. 833.00
Frequently asked questions
Anthem Biosciences is an active public limited company based in Bangalore, Karnataka, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 13 June 2006 (20+ years old) and is registered under CIN L24233KA2006PLC039703. Listed on BSE: 544449 and NSE: ANTHEM.
Anthem Biosciences reported revenue of ₹2,124.33 Cr for FY 2025-26 (up 15.2% YoY) based on consolidated financials.
Anthem Biosciences has 8 current directors:
- Ajay Bhardwaj - Managing Director
- Ganesh Sambasivam - Whole-Time Director
- K Ravindra Chandrappa - Whole-Time Director
- Shubha Kulkarni - Director
- Ramadurai Ramesh - Director
- Satish Chander Subbanna - Nominee Director
- Subramanian Madhavan - Director
- Ravikant Uppal - Director
The latest financial statements of Anthem Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 10 June 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Anthem Biosciences is 29AAFCA7588P1ZN, registered in Karnataka. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Anthem Biosciences is L24233KA2006PLC039703. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Anthem Biosciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 544449) and NSE (symbol: ANTHEM).
Anthem Biosciences has 11 court cases on record: 5 filed by the company and 6 filed against it. 4 are pending. Most are in the district courts.
Anthem Biosciences was incorporated on 13 June 2006, making it 20+ years old. It is registered with the Registrar of Companies, Bangalore.
Anthem Biosciences has 16 deals on record (7 secondary share transfers, 5 funding rounds, 3 market trades), with disclosed funding of ₹644.84 Cr; the latest was in June 2026.
The peers of Anthem Biosciences by revenue are Laurus Labs Limited, Amneal Pharmaceuticals Private Limited, Indoco Remedies Limited, Onesource Specialty Pharma Limited, all in the Pharma industry (Biosciences, Contract Research), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ganesh Sambasivam ceased to be Director on 09 Jun 2025. K Ravindra Chandrappa ceased to be Director on 09 Jun 2025. Ramadurai Ramesh was appointed as Director on 27 Sep 2024. Anthem Biosciences has 11 board changes on record in total.